International journal of hematology · 2026
Metabolic mimic of inherited bone marrow failure: LMBRD1 (cblF) deficiency in an infant.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tulsiyan Aditi, Bhattacharya Sudipto, Singh Anuj, Nilay Mayank, Singh Savitri, Radhakrishnan Nita
Аннотация
BACKGROUND: Disorders of intracellular cobalamin metabolism are rare but treatable conditions that mimic bone marrow failure syndromes.
CASE: An eight-month-old male presented with macrocytic anemia, reticulocytopenia, neutropenia, infections, failure to thrive, and developmental delay. Bone marrow examination showed hypocellularity with paucity of myeloid precursors, dysplastic megakaryocytes, fibrosis, and cytoplasmic vacuolization of hematopoietic precursors. Whole-exome-sequencing identified a homozygous LMBRD1 variant (c.907C > A; p.Pro303Thr), confirmed by parental segregation. Treatment with parenteral hydroxocobalamin resulted in partial improvement.
CONCLUSION: LMBRD1-related cblF deficiency is an exceptionally rare but treatable mimic of inherited bone marrow failure. Early recognition enables targeted therapy.
CASE: An eight-month-old male presented with macrocytic anemia, reticulocytopenia, neutropenia, infections, failure to thrive, and developmental delay. Bone marrow examination showed hypocellularity with paucity of myeloid precursors, dysplastic megakaryocytes, fibrosis, and cytoplasmic vacuolization of hematopoietic precursors. Whole-exome-sequencing identified a homozygous LMBRD1 variant (c.907C > A; p.Pro303Thr), confirmed by parental segregation. Treatment with parenteral hydroxocobalamin resulted in partial improvement.
CONCLUSION: LMBRD1-related cblF deficiency is an exceptionally rare but treatable mimic of inherited bone marrow failure. Early recognition enables targeted therapy.